Back to discover

Protein / target

Matrix metalloproteinase-14

Encoded byMMP14P50281Homo sapiensSwiss-Prot
UniProt: P50281Ensembl: ENSG00000157227HGNC: HGNC:7160NCBI Gene: 4323
Clinical-stage
Therapeutic maturity
2
Clinical candidates
4
Clinical trials
Small-molecule tractable
Druggability
Advanced Clinical

Protein at a glance

Biological role

Serine-type endopeptidase

Strongest disease association

Dupuytren Contracture

Via encoding gene MMP14 · Genetic evidence · score 0.64

Therapeutic position

Clinically advancing target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Endopeptidase that degrades various components of the extracellular matrix such as collagen.

View complete UniProt function annotation

Endopeptidase that degrades various components of the extracellular matrix such as collagen (PubMed:8015608). Essential for pericellular collagenolysis and modeling of skeletal and extraskeletal connective tissues during development (By similarity). Activates progelatinase A/MMP2, thereby acting as a positive regulator of cell growth and migration (PubMed:22065321, PubMed:8015608). Involved in the formation of the fibrovascular tissues in association with pro-MMP2 (PubMed:12714657, PubMed:22065321). May be involved in actin cytoskeleton reorganization by cleaving PTK7 (PubMed:20837484). Acts as a regulator of Notch signaling by mediating cleavage and inhibition of DLL1 (PubMed:21572390). Cleaves ADGRB1 to release vasculostatin-40 which inhibits angiogenesis (PubMed:22330140). Acts as a negative regulator of the GDF15-GFRAL aversive response by mediating cleavage and inactivation of GFRAL (PubMed:35177851)

Subcellular location

Cell membraneMelanosomeCytoplasm
Domains and Gene Ontology detail (48)

Gene Ontology

  • Ccytoplasmic vesicle
  • Cextracellular matrix
  • Cextracellular space
  • Cfocal adhesion
  • CGolgi lumen
  • Cmacropinosome
  • Cmelanosome
  • Cnucleus
  • Cplasma membrane
  • Fendopeptidase activity
  • Fintegrin binding
  • Fmetalloaminopeptidase activity

582 aa · 66 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOCell adhesionUniProt · GOProteolysisGO
View supporting evidence

Cell migration

  • ·astrocyte cell migration
  • ·cell motility
  • ·positive regulation of cell migration

Cell adhesion

  • ·Endopeptidase that degrades various components of the extracellular matrix such as colla…
  • ·extracellular matrix
  • ·extracellular matrix disassembly
  • ·extracellular matrix organization

Proteolysis

  • ·endopeptidase activity
  • ·metalloaminopeptidase activity
  • ·metalloendopeptidase activity
  • ·serine-type endopeptidase activity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Rebimastat
Phase 3Inhibitor

Matrix metalloproteinase 14 inhibitor

Direct interaction with this protein · 1 of 6 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene MMP14

Gene-level evidence surfaced through the gene MMP14that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Dupuytren Contracture
0.64Moderately supported

Genetic evidence dominant · Open Targets 0.39

Prostate carcinoma
0.54Moderately supported

Genetic evidence dominant · Open Targets 0.32

Pericarditis
0.48Limited support

Genetic evidence dominant · Open Targets 0.29

Carcinoma, Non-Small-Cell Lung
0.45Limited support

Clinical evidence dominant · Open Targets 0.33

Prostatic Neoplasms
0.40Limited support

Clinical evidence dominant · Open Targets 0.30

View evidence synthesis (5)
Dupuytren ContractureModerately supported
0.64
agreement 0.50–0.78
Genetic98%Literature2%

Open Targets aggregate 0.39 · 2 independent evidence families

Prostate carcinomaModerately supported
0.54
agreement 0.41–0.68
Genetic86%Literature14%

Open Targets aggregate 0.32 · 2 independent evidence families

PericarditisLimited support
0.48
agreement 0.36–0.60
Genetic100%

Open Targets aggregate 0.29 · 1 independent evidence family

Carcinoma, Non-Small-Cell LungLimited support
0.45
agreement 0.29–0.60
Clinical76%Literature24%

Open Targets aggregate 0.33 · 2 independent evidence families

Prostatic NeoplasmsLimited support
0.40
agreement 0.25–0.56
Clinical82%Literature18%

Open Targets aggregate 0.30 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Dupuytren Contracture0.39
Carcinoma, Non-Small-Cell Lung0.33
Prostate carcinoma0.32
Prostatic Neoplasms0.30
Pericarditis0.29
Sarcoma, Kaposi0.28

Drug development

2 compounds recorded · 2 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph: these count different sets and are not a subset relation.

View all recorded compounds (2)
CTS-1027Phase 2
REBIMASTATPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Strong

Advanced Clinical and Structure with Ligand support this modality.

Antibodies — Emerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (10)
SM · Advanced ClinicalSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

4

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

A Phase II/III Double Blind Randomized Trial of BMS-275291 vs. Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-small Cell Lung CancerPHASE2/PHASE3

COMPLETED · via Rebimastat · NCT00006229

Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate CancerPHASE2

COMPLETED · via Rebimastat · NCT00040755

A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa™) and BMS-275291 (NSC#713763) in Patients With Hormone Refractory Prostate CancerPHASE2

COMPLETED · via Rebimastat · NCT00039104

A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's SarcomaPHASE1/PHASE2

COMPLETED · via Rebimastat · NCT00024024

ClinicalTrials.gov via the drug-target graph.